Prostate Cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals.

Area of Science:

• Oncology
• Urology
• Medical Imaging

Background:

• Prostate cancer is the most prevalent cancer in men globally.
• It is the second leading cause of cancer death in the US.
• Survival rates drastically decrease with metastatic spread.

Purpose of the Study:

• To highlight the significance of prostate cancer.
• To outline current diagnostic and assessment methods.
• To emphasize the importance of early detection and risk stratification.

Main Methods:

• Review of prostate cancer statistics and survival data.
• Description of diagnostic tools: Prostate-Specific Antigen (PSA) levels, Gleason score from prostate biopsy.
• Inclusion of advanced imaging techniques: prostate MR imaging, PSMA-PET/CT.

Main Results:

• Nearly 100% 5-year survival for non-metastatic prostate cancer.
• Approximately 30% 5-year survival for metastatic prostate cancer.
• Advanced imaging aids in assessing high-risk patients.

Conclusions:

• Prostate cancer diagnosis relies on a combination of biomarkers and imaging.
• Timely and accurate assessment is crucial for patient outcomes.
• Effective management strategies are essential for improving survival rates.